Short Interest in Fortress Biotech, Inc. (NASDAQ:FBIOP) Increases By 1,056.5%

Fortress Biotech, Inc. (NASDAQ:FBIOP) was the target of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 26,600 shares, an increase of 1,056.5% from the November 30th total of 2,300 shares. Based on an average daily trading volume, of 18,600 shares, the short-interest ratio is currently 1.4 days.

Fortress Biotech Stock Down 3.6 %

FBIOP traded down $0.24 during trading hours on Thursday, hitting $6.36. The company’s stock had a trading volume of 12,140 shares, compared to its average volume of 17,460. The company has a 50-day simple moving average of $5.92 and a 200 day simple moving average of $7.70. Fortress Biotech has a fifty-two week low of $4.86 and a fifty-two week high of $18.00.

About Fortress Biotech

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.